Oragenics completes acquisition of Odyssey Health including neuro drug, tech pipelines

Oragenics Inc. has announced the completion of its acquisition of assets related to Odyssey Health Inc., including its proprietary neurological drug therapies and technologies.
According to a joint release, chief among Odyssey’s assets included in the transaction first announced in early October is ONP-002, an intranasal formulation under development to treat moderate to severe concussion in the acute through subacute phases. The novel therapeutic demonstrated safety and tolerability in a phase 1 clinical trial that included healthy human subjects, according to the release. Oragenics is

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart